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a b s t r a c t
The characteristics of active tuberculosis in cancer patients in Japan and the effects of this infection on
cancer treatment have not yet been clarified. The records of all consecutive patients with microbio-
logically documented Mycobacterium tuberculosis infection diagnosed between September 2002 and
March 2008 at Shizuoka cancer center (a 557-bed tertiary care cancer center in Japan) were reviewed.
There were 24 cancer patients with active tuberculosis during the study period. Of these, 23 had solid-
organ tumors, and the most common site of the underlying malignancy was the lung. Most of the
patients had pulmonary tuberculosis. Among 15 patients followed up for more than 2 months prior to
the diagnosis of pulmonary tuberculosis, 12 had healed scars suggestive of old tuberculosis lesions, as
shown by chest imaging obtained at the time of the initial evaluation. Discontinuation of cancer
therapy or more than a month’s delay in surgery occurred in 10 patients with pulmonary tuberculosis.
Development of active tuberculosis can delay cancer treatment in Japanese centers. Cancer patients
with scars suggestive of old tuberculosis disease lesions as shown by chest imaging should be
screened for active tuberculosis and carefully followed up. In some cases, prophylactic treatment
should be considered.
 2013, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. All rights reserved.
1. Introduction
Malignancy is a known risk factor for the development of
active tuberculosis [1]. At the same time, immunosuppressive
anti-tumor treatment is widely used among cancer patients in
those countries with high rates of tuberculosis infection. Previ-
ous reports from the United States, which has a low prevalence of
tuberculosis infection, showed that US-born cancer patients with
an underlying solid tumor had the same tuberculosis rate as US-
born patients without cancer [2e4]. Because the incidence of
tuberculosis is affected by the prevalence of tuberculosis in the
cancer patient population, we need to consider the locally
specific data to establish the ideal strategies for screening, early
detection, and treatment of latent tuberculosis infections. How-
ever, the characteristics of active tuberculosis in cancer patients
in Japan and the effects of this infection on cancer treatment
have not yet been clarified. This is partly because of the absence
of infectious disease departments in Japanese cancer center
hospitals. Here, we describe the characteristics of cancer patients
with active Mycobacterium tuberculosis infection at a tertiary
cancer center hospital in Japan, and consider the suitable man-
agement strategies for cancer patients in a country that is
intermediately endemic for tuberculosis.
2. Patients and methods
2.1. Definitions
We reviewed the records of all consecutive patients with
microbiologically documented M. tuberculosis infection
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diagnosed between September 2002 and March 2008 at the
Shizuoka cancer center (a 557-bed tertiary care cancer center in
Japan). The patients were identified from a microbiology data-
base previously established for patients with M. tuberculosis
isolated from any body site. Patient information was obtained
from electronic medical records.
2.2. Definition of tuberculosis patients
Microbiologically documented M. tuberculosis infection was
defined when clinical specimens were found to be positive by
culture or polymerase chain reaction (PCR; Roche AMPLICOR MTB
test).
2.3. Neutropenia and lymphopenia
Neutropenia was defined as an absolute neutrophil count lower
than 500/mL at the time when samples growing M. tuberculosis
were obtained. Lymphopenia was defined as an absolute lympho-
cyte count of lower than 500/mL at the time when samples growing
M. tuberculosis were obtained.
2.4. Systemic corticosteroid use
Systemic corticosteroid use was defined at a dose of more than
1 mg/(kg day) of prednisone or an equivalent dose of another
corticosteroid given within the 4 weeks before diagnosis of
infection.
2.5. Radiographic findings
Radiographic findings were reviewed by 2 investigators (M.
Endo and T. Fujita), including a radiology specialist (M. Endo).
2.6. Deaths attributable to Mycobacterium infections
Deaths were attributed toM. tuberculosis if the patient died with
progressive tuberculosis within 4 weeks of infection diagnosis.
3. Results
3.1. Patients and disease characteristics (Table 1)
There were 24 cancer patients with active tuberculosis during
the period studied. Eighteen patients (75%) were men and 6 (25%)
were women. The median age was 72 years (range, 56e89 years).
Twenty-three patients had solid-organ tumors. The one patient
with hematological malignancy had non-Hodgkin lymphoma. The
most common site for the underlying malignancy was the lung (6
patients). Four patients (17%) had received systemic corticosteroids.
Four patients had lymphopenia, and 1 had concomitant neu-
tropenia. Twenty-one patients (88%) had pulmonary tuberculosis, 2
(8%) had tuberculous lymphadenitis, and 1 (4%) had intestinal
tuberculosis. Among symptomatic patients, the most common
symptoms were fever (11 patients) and sputum (11 patients). The
tuberculosis that developed in 7 patients during or within 30 days
of chemotherapy was found to be pulmonary tuberculosis. No pa-
tients had ever received anti-tuberculosis drugs. Seven patients
were asymptomatic, and 6 of these only had abnormal findings on
plain chest radiography or pulmonary computed tomography (CT).
One patient was found on CT to have lymph node adenopathy,
which was considered metastatic pancreas cancer. The antimicro-
bial susceptibility status of 21M. tuberculosis isolates was available.
All strains tested were found to be susceptible to isoniazid,
rifampin, pyrazinamide, and ethambutol. Among 21 pulmonary
tuberculosis patients, 16 were diagnosed by sputum, 3 by bron-
choalveolar lavage (BAL), 1 by both sputum and BAL, and 1 by lung
biopsy. Twelve patients (54%) had smear-positive sputum. Of the 7
patients who developed active tuberculosis during or within 30
days of chemotherapy, 4 (57%) were smear-positive.
Fifteen patients received follow-up for more than 2 months
prior to the diagnosis of tuberculosis (range, 2e35 months). Of
these patients, 12 (12/15: 80%) had healed scars suggestive of old
tuberculosis lesions as shown by plain chest radiography or CT
obtained at initial evaluation at presentation to our hospital.
All 7 patients who developed active tuberculosis during or
within 30 days of chemotherapy had pulmonary tuberculosis. Of
these patients, 5 had healed scars suggestive of old tuberculosis
lesions, 1 had chronic bronchitis, and 1 patient had old nonspecific
pleurisy on chest radiography or chest CT taken before the initia-
tion of chemotherapy. Six patients were diagnosed with simulta-
neous active tuberculosis and malignancy. Three patients had been
followed by another institute for cancer and were referred to our
hospital for further investigation, where they were diagnosed with
tuberculosis. Of the 12 patients who had healed scars suggestive of
old tuberculosis lesions, 7 (58%) had no history of tuberculosis.
Death was attributed toM. tuberculosis diseases in 1 patient who
developed the disease during chemotherapy for pancreatic cancer,
and then developed acute respiratory distress syndrome. Delay of
cancer therapy (discontinuation of chemotherapy, or more than a
month’s delay in surgery) was necessary in 10 patients with pul-
monary tuberculosis.
4. Discussion
To the best of our knowledge, this is the first report in English to
detail the characteristics of patients with tuberculosis and cancer in
a Japanese tertiary cancer center hospital. The present study
demonstrated that patients with tuberculosis at our Japanese ter-
tiary care cancer center who had lung cancer as their most common
underlying disease were older than similar patients in the United
States [2,3]. Seven (29%) patients were asymptomatic and had no
identifiable risk factors other than malignancy such as corticoste-
roid administration. During initial evaluation at our institute, we
Table 1
Patient characteristics.
Patient characteristics No. of patients (%)
Underlying cancer
Lung 6 (25)
Esophagus 3 (13)
Colon 3 (13)
Stomach 2 (8)
Prostate 2 (8)
Pharynx 2 (8)
Pancreas 2 (8)
Breast 2 (8)
Thyroid 1 (4)
Non-Hodgkin lymphoma 1 (4)
Site of infection
Lung 21 (88)
Lymph node 2 (8)
Intestine 1 (4)
Clinical presentation
Fever 11 (46)
Sputum 11 (46)
Cough 8 (33)
Asymptomatic 7 (29)
Asymptomatic and abnormal chest radiograph 6 (25)
Weight loss 4 (17)
Dyspnea 3 (13)
Lymph node adenopathy 2 (8)
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commonly observed healed scars suggestive of old tuberculosis
lesions. Thirteen (54%) patients were smear-positive and had to be
transferred to other specialty tuberculosis hospitals, as specified by
Japanese law. In some patients, cancer therapy was delayed during
tuberculosis treatment.
While lung cancer was the most common underlying malig-
nancy noted at our institute, several other previous reports, in
similar institutes, describe a more diverse set of underlying ma-
lignancies. In Korea, for example, the most common underlying
malignancy has been shown to be stomach cancer [5,6], while in
the United States, hematological malignancies were the most
common underlying malignancy [2]. These differences might
depend on the type of cancer patients treated at each institute. In
Japan, for instance, 1% of lung cancer patients also have pulmonary
tuberculosis. This reported rate is 25 times higher than that in the
general population [7]. This value could also be influenced by
repeat radiographic evaluation of lung cancer patients, which could
increase the number of these cases being reported.
Patients diagnosed with active tuberculosis at our institute
were, on average, older than their counterparts in the United States
[2,3]. This reflects the fact that half a century ago, tuberculosis was
an endemic disease in Japan. In European and North American
countries, tuberculosis is a disease of immigrants, especially those
emigrating from endemic areas. By contrast, in Japan, a rapidly
developing country over the last few decades, tuberculosis is a
disease of elderly people. The affected individuals survived the
endemic era before the introduction of anti-tuberculosis drugs.
Therefore, in Japan, tuberculosis patients with cancer share char-
acteristics with other tuberculosis patients in Japan: they are of
advanced age and their pulmonary tuberculosis is a reactivation,
often of a disease that has been previously “healed”. The estimated
prevalence of tuberculosis infection in the aging Japanese popula-
tion (>70 years) has been estimated at >60%. This value is
increasing with advancing age and shows a rapid decline in the
generation born after 1945 (following the end of World War II), a
positive turning point in Japanese public health status [8].
The healed scar suggesting previous tuberculosis on chest
radiography was characteristic of cancer patients with active
tuberculosis at our institute. Because many older patients do not
present with respiratory symptoms [9], radiographical evaluation is
critical to detecting pulmonary tuberculosis in patients with cancer.
In Korea, it has been reported that most cancer patients with pul-
monary tuberculosis have healed scars suggesting previous tuber-
culosis on chest radiography [5,6]. In a case series where Kim
reported the characteristics of solid-organ malignancy patients
with pulmonary tuberculosis, healed scars suggesting previous
tuberculosis on chest radiography were found in most patients,
regardless of whether they had received anti-TB chemotherapy [6].
This suggests that the disease was caused by reactivation of latent
infection. However, patients not receiving anti-cancer chemo-
therapy were also found to have healed scars. Thus, this reac-
tivation may reflect the immunodeficiency effect of the malignant
disease itself. In this report by Kim, the proportion of patients who
received anti-cancer chemotherapy among 305 patients with
healed scars is unclear. It is known that latent tuberculosis patients
with healed scars have a high risk of reactivation [10]. The additive
effect of anti-cancer chemotherapy on reactivation of tuberculosis
in solid-organ cancer patients with old radiographic lesion is not
well defined.
The characteristics of tuberculosis patients described in this
report are suggestive of high-risk patients who need careful esti-
mation of tuberculosis risk and assessment of the necessity of
latent tuberculosis treatment before or during immunosuppressive
therapy of their malignant diseases. In the present study, we found
that old radiographic changes, identified at initial evaluation and
before commencement of cancer treatment, were common in
Japanese tuberculosis patients. Therefore, we propose that it is
important to carry out pulmonary radiographic evaluation prior to
treatment. Changes in chest radiography findings, especially in case
of fibronodular disease, is a risk factor for the development of active
tuberculosis [11]. Cancer patients exhibiting these radiographic
changes should be considered for further evaluation through
interferon-gamma release assays (IGRA) or treatment of latent
tuberculosis infection (LTBI) infection before or during anti-cancer
chemotherapy. Guidelines issued by the Japanese Society for
Tuberculosis regarding treatment for LTBI do not effectively discuss
possible risk factors in cancer patients for developing active
tuberculosis nor do they indicate that cancer patients are possible
candidates for LTBI treatment [12]. The diversity in the immuno-
compromised status among cancer patients makes it challenging to
determine a common strategy for diagnosis and treatment of LTBI
across all types of cancer. Therefore, more elderly cancer patients,
for example, could be further evaluated according to other indi-
vidual risk factors such as concomitant diabetes or corticosteroid
administration to best determine their need for LTBI treatment. It is
unclear whether the benefit of treating latent tuberculosis infection
exceeds the risk of drug side effects in cancer patients receiving
anti-cancer chemotherapy. Tuberculosis reactivation during anti-
cancer chemotherapy can be safely treated [5]. Therefore, close
observation of patients to ensure early detection is also a clinically
relevant option.
Our study showed that tuberculosis could be a reason for the
delay in cancer treatment. Because the Japanese law mandates
that smear-positive patients be transferred to a tuberculosis ward,
surgery and chemotherapy in such patients were postponed until
their discharge. Smear-negative patients and smear-positive pa-
tients who were discharged from tuberculosis wards were treated
at our institute by physicians specializing in infectious diseases.
Anti-cancer therapy was restarted only after at least 2 weeks,
when infectivity is considered to be decreased. If anti-cancer
chemotherapy or surgery could be safely postponed, we with-
held anti-cancer therapy until 2 months after initial anti-
tuberculosis treatment was completed. Although the prognostic
effect is unclear, this approach might negatively affect prognosis
because treatment delay might result in cancer progression. Early
re-initiation of cancer therapy is crucial and can be achieved by
coordination between infectious disease specialists and oncolo-
gists. To reduce the delay in cancer treatment for tuberculosis
patients, all cancer hospitals in Japan should have an infectious
disease department.
This study has several limitations. First, this is a retrospective
study at a single center, with a relatively small number of patients.
Prospective multicenter investigations in cancer hospitals in Japan
are required to allow for better comparison between nationwide
tuberculosis epidemiology and that of cancer. Furthermore, there
was a lack of information on purified protein derivative treatment,
IGRA performance, and Bacillus CalmetteeGuerin vaccination sta-
tus, because patients were recruited on the basis of microbiological
examination. Although these data are not essential for the diag-
nosis of active tuberculosis, cases diagnosed only on the basis of
clinical suspicion might not be included in this study. Finally, we
did not collect data regarding cancer progression, such as TNM
stage and histopathological classification. Cancer progression is
associated with tuberculosis development because patients with
advanced cancer have compromised immunity. There are currently
no global guidelines to distinguish between the terms “advanced”
and “non-advanced” cancer with regard to immunosuppression
status. Hence, the risk of tuberculosis reactivation associated with
cancer progression must be assessed on a case-by-case basis using
best clinical judgment.
T. Fujita et al. / J Infect Chemother 20 (2014) 213e216 215
In conclusion, we believe that cancer patients presenting evi-
dence of healed scars on chest images, suggestive of old tubercu-
losis disease lesions, should be screened for active tuberculosis and
carefully followed up. In some cases, prophylactic treatment should
be considered. Further prospective studies are needed to clarify
whether high-risk cancer patients would benefit from screening,
including IGRA, and from treatment of latent tuberculosis infection
before or during their anti-cancer treatment.
Conflict of interest
All authors declare no conflicts of interest.
Acknowledgments
Part of this study was presented as a poster (poster number K-
1406) at the Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC)/Infectious Disease Society of America
(IDSA) annual meeting on October 2008, in Washington DC, USA.
References
[1] Targeted tuberculin testing and treatment of latent tuberculosis infection.
American Thoracic Society. MMWR Recomm Rep 2000;49:1e51.
[2] Aisenberg GM, Jacobson K, Chemaly RF, Rolston KV, Raad II, Safdar A.
Extrapulmonary tuberculosis active infection misdiagnosed as cancer: Myco-
bacterium tuberculosis disease in patients at a Comprehensive Cancer Center
(2001e2005). Cancer 2005;104:2882e7.
[3] De La Rosa GR, Jacobson KL, Rolston KV, Raad II, Kontoyiannis DP, Safdar A.
Mycobacterium tuberculosis at a comprehensive cancer centre: active disease
in patients with underlying malignancy during 1990e2000. Clin Microbiol
Infect 2004;10:749e52.
[4] Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin
Infect Dis 2006;42:1592e5.
[5] Kim DK, Lee SW, Yoo C-G, Kim YW, Han SK, Shim Y-S, et al. Clinical charac-
teristics and treatment responses of tuberculosis in patients with malignancy
receiving anticancer chemotherapy. Chest 2005;128:2218e22.
[6] Kim H-R, Hwang SS, Ro YK, Jeon CH, Ha DY, Park SJ, et al. Solid-organ ma-
lignancy as a risk factor for tuberculosis. Respirology 2008;13:413e9.
[7] Sugino K, Homma S, Miyamoto A, Takaya H, Sakamoto S, Kawabata M, et al.
Clinical analysis of lung cancer complicated by pulmonary tuberculosis. Jpn J
Lung Cancer 2007;47:97e103.
[8] Statistics of TB. Available at: http://www.jata.or.jp/rit/rj/data_tp.html
[accessed 18.09.08].
[9] Ohmori M, Wada M, Mitarai S, Hoshino H, Yanai H, Yoshiyama T, et al. Studies
on the process of discovery of the hospitalized elderly TB patients. Kekkaku
2004;79:243.
[10] Groth-Petersen E, Knudsen J, Wilbek E. Epidemiological basis of tuberculosis
eradication in an advanced country. Bull World Health Organ 1959;21:5e49.
[11] Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to
go next? Int J Tuberc Lung Dis 2008 Dec;12:1352e64.
[12] Kato S, Nishimura N, Takanashi S, Igari H, Inagaki T, Izumi S, et al. Treatment
guidelines for latent tuberculosis infection. Kekkaku 2013;88:497e512.
T. Fujita et al. / J Infect Chemother 20 (2014) 213e216216
